RESUMEN
A simple, reliable a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, (MTS) assay was conducted to evaluate the potential cytotoxic effects of levodopa, a "gold standard therapy" for Parkinsonism, and its complex with Hydroxypropyl-ß-Cyclodextrin (HP-ß-CD) on an astrocyte cell line. The cells were incubated in a range of concentrations from 4.69 to 300 µg/mL levodopa, HP-ß-CD or the complex for up to 72 hours. At every 24-hour interval, the optical density (OD), which reflects the number of viable cells, was recorded. In general, linear dose-dependent cytotoxicity profiles were observed for the cells subjected to levodopa or the complex, whereas a slightly triphasic response was observed for the cells exposed to HP-ß-CD. A significant difference (P < 0.05) in cytotoxicity was detected between the HP-ß-CD-treated group and the levodopa-treated group. In particular, we observed that the cells treated with the complex, even at the highest concentrations (> 200 µg/mL), exhibited improved tolerability in a time-dependent manner, which may indicate the potential ability of HP-ß-CD to mask the toxic effects of levodopa via complexation.
RESUMEN
The possible cytotoxic effects of vancomycin and its complex with beta-cyclodextrin (ß-CD) on human glial cell line (CRL 8621) were studied accordingly by means of MTS assay. The cultured cells were incubated with various concentrations of vancomycin, ß-CD as well as ß-CD/vancomycin complex ranging from 4.69 to 300 ug/ml. A linear dose-dependency cytotoxicity followed by hermetic-like biphasic dose-dependence was observed after incubation period of 72 hours. In general, significant increase (p<0.001) of cell proliferation was observed at lower concentrations: <18.75 µg/ml for cells treated with ß-CD and their complex while < 9.38 µg/ml for cells treated with vancomycin. In contrary, regardless of the treatments given, significant (p<0.001) reduce in cell survival was found at higher concentrations >150 µg/ml. In particular, 50 % inhibitory in vitro was achieved at the concentrations of 115.95 µg/ml (for ß-CD), 116.48 µg/ml (for vancomycin) and 115.44 µg/ml (for ß-CD/vancomycin complex).